Zyla Life Sciences (OTCQX: ZCOR), a growing commercial-stage life sciences company, announced the appointment of Gary M. Phillips, M.D. to its board of directors.

"Gary brings to Zyla a wealth of experience from working in the pharmaceutical industry in a range of commercial, business development, strategy and clinical development leadership positions," said Timothy P. Walbert, Zyla chairman of the board and chairman, president and chief executive officer (CEO) of Horizon Therapeutics. "With our focus on driving commercial growth at Zyla, Gary's commercial experience will be helpful."

Over the past two decades, Dr. Phillips has worked in leadership roles at life sciences and pharmaceutical companies. He currently is the president and CEO of OrphoMed, Inc., a biopharma company focused on gastrointestinal diseases and pain. Prior to OrphoMed, Dr. Phillips was executive vice president and chief strategy officer at Mallinckrodt Pharmaceuticals for five years. Previously, he was Head of Global Health & Healthcare Industries at the World Economic Forum. Earlier, he was president of Reckitt Benckiser Pharmaceuticals North America (now Indivior) and held dual roles as president, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb. Additionally, Dr. Phillips served in executive roles at Merck Serono, Novartis and Wyeth.

"With the expected growth coming from the recent acquisition of five approved products and legacy products, it is an exciting time to join the Zyla board," said Dr. Phillips. "I am looking forward to working with management and the board to drive further growth of the company and helping to evaluate new opportunities."

Luke Düster has stepped down from the board of directors effective immediately.

"We look forward to working with Dr. Phillips and want to thank Luke for his contributions to the Board," said Bob Radie, president and CEO at Zyla.

Dr. Phillips earned his bachelor's degree in Biochemistry with Summa Cum Laude and Phi Beta Kappa distinctions, an MBA and a medical degree with Alpha Omega Alpha distinction all from the University of Pennsylvania. Dr. Phillips practiced as a general medicine clinician/officer in the U.S. Navy and maintains an active medical license.

About Zyla Life Sciences

Zyla Life Sciences is a business committed to bringing important products to patients and healthcare providers. Zyla is focused on marketing its portfolio of medicines for pain and inflammation. The company portfolio includes seven products: SPRIX® (ketorolac tromethamine) Nasal Spray, ZORVOLEX® (diclofenac), VIVLODEX® (meloxicam), TIVORBEX®indomethacin), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only —CII.

For full prescribing information, boxed warnings and medication guides, please visit the following sites for each product: sprix.com, vivlodex.com, zorvolex.com, tivorbex.com, and oxaydo.com. Prescribing information, the boxed warning and medication guide for INDOCIN suppositories and oral suspension can be found at dailymed.nlm.nih.gov.